Interpace Biosciences, Inc. (IDXG)
USD 1.18
(-8.01%)
USD 1.18
(-8.01%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 40.21 Million USD | 26.31% |
| 2022 | 31.83 Million USD | -22.94% |
| 2021 | 41.31 Million USD | 27.52% |
| 2020 | 32.39 Million USD | 34.55% |
| 2019 | 24.07 Million USD | 9.97% |
| 2018 | 21.89 Million USD | 37.74% |
| 2017 | 15.89 Million USD | 21.49% |
| 2016 | 13.08 Million USD | 38.73% |
| 2015 | 9.43 Million USD | -92.14% |
| 2014 | 119.93 Million USD | -20.49% |
| 2013 | 150.84 Million USD | 18.87% |
| 2012 | 126.89 Million USD | -19.32% |
| 2011 | 157.29 Million USD | 8.74% |
| 2010 | 144.65 Million USD | 70.44% |
| 2009 | 84.87 Million USD | -24.58% |
| 2008 | 112.52 Million USD | -3.93% |
| 2007 | 117.13 Million USD | -51.04% |
| 2006 | 239.24 Million USD | -25.1% |
| 2005 | 319.41 Million USD | -12.36% |
| 2004 | 364.44 Million USD | 14.8% |
| 2003 | 317.44 Million USD | 11.77% |
| 2002 | 284.01 Million USD | -59.23% |
| 2001 | 696.58 Million USD | 67.1% |
| 2000 | 416.87 Million USD | 138.35% |
| 1999 | 174.9 Million USD | 73.0% |
| 1998 | 101.1 Million USD | 84.83% |
| 1997 | 54.7 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 10.27 Million USD | -0.1% |
| 2024 Q2 | 12.04 Million USD | 17.22% |
| 2024 Q3 | 12.29 Million USD | 2.1% |
| 2023 Q4 | 10.28 Million USD | 13.27% |
| 2023 Q2 | 11.02 Million USD | 12.21% |
| 2023 Q3 | 9.07 Million USD | -17.67% |
| 2023 Q1 | 9.82 Million USD | 17.93% |
| 2023 FY | 40.21 Million USD | 26.31% |
| 2022 Q4 | 8.33 Million USD | 1.75% |
| 2022 FY | 31.83 Million USD | -22.94% |
| 2022 Q1 | 10.37 Million USD | -4.39% |
| 2022 Q2 | 9.35 Million USD | -9.89% |
| 2022 Q3 | 8.18 Million USD | -12.43% |
| 2021 Q1 | 9.83 Million USD | 1.94% |
| 2021 FY | 41.31 Million USD | 27.52% |
| 2021 Q3 | 9.47 Million USD | -15.09% |
| 2021 Q2 | 11.15 Million USD | 13.44% |
| 2021 Q4 | 10.85 Million USD | 14.58% |
| 2020 Q2 | 5.44 Million USD | -40.8% |
| 2020 Q4 | 9.64 Million USD | 16.95% |
| 2020 Q3 | 8.24 Million USD | 51.45% |
| 2020 Q1 | 9.2 Million USD | 125.88% |
| 2020 FY | 32.39 Million USD | 34.55% |
| 2019 FY | 24.07 Million USD | 9.97% |
| 2019 Q1 | 6.01 Million USD | 3.02% |
| 2019 Q2 | 6.27 Million USD | 4.33% |
| 2019 Q3 | 7.72 Million USD | 23.21% |
| 2019 Q4 | 4.07 Million USD | -47.28% |
| 2018 Q2 | 5.5 Million USD | 14.39% |
| 2018 FY | 21.89 Million USD | 37.74% |
| 2018 Q4 | 5.83 Million USD | 1.41% |
| 2018 Q3 | 5.75 Million USD | 4.58% |
| 2018 Q1 | 4.8 Million USD | 10.05% |
| 2017 FY | 15.89 Million USD | 21.49% |
| 2017 Q4 | 4.37 Million USD | 4.0% |
| 2017 Q3 | 4.2 Million USD | 9.0% |
| 2017 Q1 | 3.47 Million USD | 11.15% |
| 2017 Q2 | 3.85 Million USD | 11.1% |
| 2016 Q2 | 3.61 Million USD | 19.01% |
| 2016 Q1 | 3.03 Million USD | 102.98% |
| 2016 Q4 | 3.12 Million USD | -5.85% |
| 2016 FY | 13.08 Million USD | 38.73% |
| 2016 Q3 | 3.31 Million USD | -8.19% |
| 2015 Q4 | -101.85 Million USD | -378.09% |
| 2015 FY | 9.43 Million USD | -92.14% |
| 2015 Q1 | 38.31 Million USD | 45.51% |
| 2015 Q2 | 36.34 Million USD | -5.16% |
| 2015 Q3 | 36.62 Million USD | 0.78% |
| 2014 FY | 119.93 Million USD | -20.49% |
| 2014 Q3 | 29.24 Million USD | -7.39% |
| 2014 Q4 | 26.33 Million USD | -9.95% |
| 2014 Q2 | 31.57 Million USD | -3.66% |
| 2014 Q1 | 32.77 Million USD | -9.99% |
| 2013 Q3 | 34.26 Million USD | -8.01% |
| 2013 Q1 | 42.92 Million USD | 20.46% |
| 2013 Q2 | 37.24 Million USD | -13.23% |
| 2013 Q4 | 36.41 Million USD | 6.29% |
| 2013 FY | 150.84 Million USD | 18.87% |
| 2012 Q2 | 27.8 Million USD | -12.21% |
| 2012 Q1 | 31.67 Million USD | -4.92% |
| 2012 Q4 | 35.63 Million USD | 12.12% |
| 2012 FY | 126.89 Million USD | -19.32% |
| 2012 Q3 | 31.78 Million USD | 14.28% |
| 2011 Q3 | 37.24 Million USD | -8.32% |
| 2011 Q2 | 40.62 Million USD | -11.88% |
| 2011 FY | 157.29 Million USD | 8.74% |
| 2011 Q4 | 33.31 Million USD | -10.55% |
| 2011 Q1 | 46.1 Million USD | 3.14% |
| 2010 Q4 | 44.7 Million USD | 24.26% |
| 2010 Q1 | 32.37 Million USD | 34.84% |
| 2010 FY | 144.65 Million USD | 70.44% |
| 2010 Q2 | 33.52 Million USD | 3.55% |
| 2010 Q3 | 35.97 Million USD | 7.31% |
| 2009 Q1 | 23.53 Million USD | -7.37% |
| 2009 Q2 | 16.29 Million USD | -30.77% |
| 2009 FY | 84.87 Million USD | -24.58% |
| 2009 Q3 | 21.04 Million USD | 29.16% |
| 2009 Q4 | 24 Million USD | 14.1% |
| 2008 Q1 | 32.22 Million USD | -1.07% |
| 2008 Q4 | 25.4 Million USD | 3.71% |
| 2008 FY | 112.52 Million USD | -3.93% |
| 2008 Q3 | 24.49 Million USD | -19.42% |
| 2008 Q2 | 30.39 Million USD | -5.68% |
| 2007 Q2 | 27.78 Million USD | -15.3% |
| 2007 Q1 | 32.8 Million USD | -41.25% |
| 2007 FY | 117.13 Million USD | -51.04% |
| 2007 Q4 | 32.57 Million USD | 35.91% |
| 2007 Q3 | 23.96 Million USD | -13.73% |
| 2006 Q3 | 51.31 Million USD | -6.61% |
| 2006 Q4 | 55.83 Million USD | 8.79% |
| 2006 Q2 | 54.95 Million USD | -30.28% |
| 2006 Q1 | 78.81 Million USD | -3.05% |
| 2006 FY | 239.24 Million USD | -25.1% |
| 2005 Q1 | 82.02 Million USD | -6.59% |
| 2005 Q2 | 79.61 Million USD | -2.94% |
| 2005 Q3 | 76.48 Million USD | -3.93% |
| 2005 Q4 | 81.29 Million USD | 6.28% |
| 2005 FY | 319.41 Million USD | -12.36% |
| 2004 Q1 | 88.36 Million USD | -4.33% |
| 2004 Q3 | 92.52 Million USD | 11.2% |
| 2004 FY | 364.44 Million USD | 14.8% |
| 2004 Q4 | 87.81 Million USD | -5.09% |
| 2004 Q2 | 83.2 Million USD | -5.84% |
| 2003 FY | 317.44 Million USD | 11.77% |
| 2003 Q2 | 71.25 Million USD | 5.5% |
| 2003 Q4 | 92.36 Million USD | 7.05% |
| 2003 Q3 | 86.28 Million USD | 21.08% |
| 2003 Q1 | 67.54 Million USD | -14.53% |
| 2002 Q4 | 79.02 Million USD | 22.4% |
| 2002 Q1 | 73.88 Million USD | -72.0% |
| 2002 Q2 | 66.53 Million USD | -9.95% |
| 2002 Q3 | 64.56 Million USD | -2.95% |
| 2002 FY | 284.01 Million USD | -59.23% |
| 2001 Q2 | 143.94 Million USD | -16.83% |
| 2001 Q4 | 263.9 Million USD | 128.14% |
| 2001 Q1 | 173.06 Million USD | -6.67% |
| 2001 Q3 | 115.67 Million USD | -19.64% |
| 2001 FY | 696.58 Million USD | 67.1% |
| 2000 FY | 416.87 Million USD | 138.35% |
| 2000 Q4 | 185.43 Million USD | 119.79% |
| 2000 Q3 | 84.36 Million USD | 11.32% |
| 2000 Q2 | 75.78 Million USD | 6.31% |
| 2000 Q1 | 71.28 Million USD | 59.13% |
| 1999 Q1 | 36 Million USD | 16.5% |
| 1999 Q2 | 43.8 Million USD | 21.67% |
| 1999 Q3 | 44.5 Million USD | 1.6% |
| 1999 FY | 174.9 Million USD | 73.0% |
| 1999 Q4 | 44.8 Million USD | 0.67% |
| 1998 Q2 | 22.1 Million USD | -5.96% |
| 1998 FY | 101.1 Million USD | 84.83% |
| 1998 Q3 | 24.6 Million USD | 11.31% |
| 1998 Q4 | 30.9 Million USD | 25.61% |
| 1998 Q1 | 23.5 Million USD | 57.72% |
| 1997 Q4 | 14.9 Million USD | 0.0% |
| 1997 Q2 | 14.9 Million USD | 49.0% |
| 1997 Q1 | 10 Million USD | 0.0% |
| 1997 FY | 54.7 Million USD | 0.0% |
| 1997 Q3 | 14.9 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Bio Medica Corporation | 913 Thousand USD | -4304.6% |
| Arrayit Corporation | 4.37 Million USD | -818.694% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 25.85 Million USD | -55.519% |
| Bioqual, Inc. | 58.59 Million USD | 31.365% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 15.29 Million USD | -162.905% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion USD | 99.455% |
| HTG Molecular Diagnostics, Inc. | 6.36 Million USD | -531.678% |
| iMD Companies, Inc. | - USD | -Infinity% |
| IDenta Corp. | 1.05 Million USD | -3724.114% |
| Integrative Health Technologies, Inc. | 447.49 Thousand USD | -8886.389% |
| InVitro International | 792.62 Thousand USD | -4973.502% |
| Lumos Diagnostics Holdings Limited | 11.13 Million USD | -261.279% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 7.22 Million USD | -456.655% |
| NovelStem International Corp. | 12 Thousand USD | -335016.667% |
| Optigenex Inc. | 465.97 Thousand USD | -8530.169% |
| PharmChem, Inc. | 6.01 Million USD | -568.851% |
| Proteome Sciences plc | 6.4 Million USD | -528.281% |
| Response Genetics, Inc | 18.04 Million USD | -122.916% |
| Rennova Health, Inc. | 13.03 Million USD | -208.48% |
| RushNet, Inc. | 1.78 Million USD | -2149.256% |
| ScreenPro Security Inc. | 1.91 Million USD | -2000.932% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 3.79 Million USD | -959.636% |
| Todos Medical Ltd. | 7.69 Million USD | -422.599% |